Collegium Pharma (NASDAQ: COLL) reported Q4 EPS of ($0.54), $0.03 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $10.8 million versus the consensus estimate of $9.88 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.